Ethics and Compliance

At Hospira, we are committed to making a difference with integrity and with high ethical standards in everything we do. To view The Summary of Pfizer Policies on Business Conduct, click here.



Open Payments or Physician Payment Sunshine Act (also known as “Sunshine”) is part of the healthcare reform act which became law in the United States in 2010. This regulation is aimed at increasing transparency in relationships between industry and medical professionals.

This regulation requires manufacturers of a covered drug, device, biological or medical supply to report individual payments or transfers of value to U.S. physicians and teaching hospitals in amounts greater than $10 per instance or $100 in aggregate in a calendar year. Hospira began tracking this information on August 1, 2013, per the regulations. The data will be displayed in a publicly viewable database in September 2014.

Hospira supports the Open Payments regulation and its goals because we recognize that transparency inspires public trust and confidence. For additional information regarding Open Payments please click the following link:

Annual Compliance Declaration

This Declaration is made by Hospira, Inc. as of July 1, 2015, in accordance with the provisions of California Health & Safety Code §§ 119400 et seq., also known as CA S.B. 1765 ("California S.B. 1765").

The California S.B. 1765 states that pharmaceutical companies shall include in their compliance programs policies for compliance with the PhRMA Code of Ethics (PhRMA Code). Because Hospira has both pharmaceutical products and medical devices within its product portfolio, Hospira has implemented a set of policies and procedures that conform with the PhRMA Code and the AdvaMed Code of Ethics. In response to CA S.B. 1765, Hospira has established an annual spending limit for educational items or activities directed toward "individual medical and healthcare professionals" in California. This annual maximum limit is $3,000 per individual medical or healthcare professional. This annual maximum limit excludes payments made for legitimate professional services provided by a health care or medical professional such as consulting. This limit also excludes disposable items given to healthcare professionals intended for free distribution to patients, printed advertisements about Hospira products given to healthcare professionals, and financial support for continuing medical education forums and for health educational scholarships.

To the best of Hospira’s knowledge and belief and based on a good faith understanding of the applicable statutory requirements, Hospira is in compliance with our Compliance Program and with the requirements of the California S.B. 1765.

For information, please contact the Compliance Helpline.

This Act requires certain manufacturers to disclose their efforts to eradicate slavery and human trafficking from their supply chains. Hospira supports the intent of this Act and is committed to conducting business in a legal and ethical manner. We expect our suppliers do so, as well. Our expectations are set forth in our Supplier Code of Conduct.

The Code addresses responsible business practices including compliance with environmental health and safety and labor laws. Hospira’s expectation is that its suppliers should treat all workers with dignity and respect. Suppliers shall be committed to non-discrimination, fair treatment, wages, benefits and working hours according to applicable law, and freely chosen employment.

For information about clinical trials conducted by Hospira, Inc., visit This information is being provided in part to ensure compliance with the State of Maine's Clinical Trial Disclosure Law (LD 1618). The information contained on these sites is not intended to replace the advice of a healthcare professional. Only a physician can determine if a specific medicine is the correct treatment for a particular patient. Nothing on this Web site or the links contained herein should be construed as the giving of advice or the making of a recommendation, and this information should not be relied on as the basis for any decision or action. The information contained on this site and the site to which this site links is not intended to promote or otherwise commercialize (directly or indirectly) any off-label or unapproved uses of Hospira products.

The information on this Web site is not intended to be used by physicians for making prescribing decisions. When making prescribing decisions, physicians should always refer to the specific labeling information approved for the patient's country or region.

Links to third party Web sites are provided for convenience only. Hospira, Inc. does not express any opinion on the content of any third party Web sites and expressly disclaims any liability for all third party information and the use of it.